GlassScriptPhysician profile
Scott A Segel
NPI 1063416535
$136,764.08
in general payments reported to CMS, 2019-2025
21 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $21K · 2021: $21K · 2022: $19K · 2023: $5,062 · 2024: $6,201 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $1,584 · Food and Beverage: $1,432 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,642.25 |
| Travel and Lodging | $1,584.01 |
| Food and Beverage | $1,431.62 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119,445.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $15,338.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.74 | 2022-2023 | Jardiance |
| Abbott Laboratories | $223.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $183.54 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $164.73 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $154.05 | 2024 | Minimed 780g |
| Sequel Med Tech, LLC | $144.58 | 2025 | Twiist |
| Dexcom, INC. | $126.32 | 2022-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $123.24 | 2019 | |
| Abbvie INC. | $120.29 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $106.00 | 2023 | |
| Radius Health, INC. | $98.38 | 2019-2020 | |
| Amgen INC. | $97.36 | 2019-2020 | |
| Lilly USA, LLC | $90.21 | 2019-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $32.74 | 2021 | |
| Merck Sharp & Dohme LLC | $28.03 | 2019 | |
| Senseonics, Incorporated | $12.00 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Segel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.